QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Quinn, J. A. Articles by Friedman, H. S. Search for Related Content PubMed PubMed Citation

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma

Departments of Surgery (J.A.Q., D.A.R., A.H.F., J.N.R., J.H.S., J.V., S.G., A.W., H.S., D.D.B., S.T.-U., M.L.A., S.J., D.A., K.Z., C.B., C.L., H.S.F.), Radiology (J.M.P.), Pathology (D.D.B), and Biostatistics and Bioinformatics (J.E.H.), Duke University Medical Center, Durham, NC 27710 USA

² Address correspondence to Jennifer Quinn, The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710 (quinn008{at}mc.duke.edu).

Abstract

Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma. We now report the results of a phase 1 trial of irinotecan plus BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, for patients with recurrent or progressive MG. Irinotecan dose escalation occurred independently within 2 strata: patients receiving enzyme-inducing antiepileptic drugs (EIAEDs) and patients not receiving EIAEDs. BCNU was administered at a dose of 100 mg/m² over 1 h every 6 weeks on the same day as the first irinotecan dose was administered. Irinotecan was administered intravenously over 90 min once weekly. Treatment cycles consisted of 4 weekly administrations of irinotecan followed by a 2-week rest with dose escalation in cohorts of 3 to 6 patients. Seventy-three patients were treated, including 49 patients who were on EIAEDs and 24 who were not on EIAEDs. The maximum tolerated dose for patients not on EIAEDs was 125 mg/m². The maximum tolerated dose for patients on EIAEDs was 225 mg/m². Dose-limiting toxicity was evenly distributed among the following organ systems: pulmonary, gastrointestinal, cardiovascular, neurologic, infectious, and hematologic, without a clear predominance of toxicity involving any one organ system. There was no evidence of increasing incidence of toxicity involving one organ system as irinotecan dose was escalated. On the basis of these results, we conclude that the recommended doses of irinotecan for a phase 2 clinical trial when given in combination with BCNU (100 mg/m²) are 225 mg/m² for patients on EIAEDs and 125 mg/m² for patients not on EIAEDs.

This article has been cited by other articles:

				A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol., December 1, 2004; 22(23): 4779 - 4786. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma Neuro-oncol, April 1, 2004; 6(2): 134 - 144. [Abstract] [PDF]